Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system

References

• American Heart Association. Atrial Fibrillation [online]. Available from www.americanheart.org [Accessed 28 Oct 2004]
   Google Scholar
• Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760–4
   PubMed Web of Science ®Google Scholar
• Petersen P, Boyson G, Godtfredsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989;1:175–9
   PubMed Web of Science ®Google Scholar
• Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505–11
   Google Scholar
• Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991;84:527–39
   Google Scholar
• Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349–55
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation (SPINAF). N Engl J Med 1992;327:1406–12
   PubMed Web of Science ®Google Scholar
• Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(Suppl):429S–456S
   Google Scholar
• ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation). Developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001;38: 1231–66
   Google Scholar
• Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999;131:927–34
   PubMed Web of Science ®Google Scholar
• Jencks SF, Cuerdon T, Burwen DR, et al. Quality of medical care delivered to Medicare beneficiaries. A profile at state and national levels. JAMA 2000;284:1670–6
   Google Scholar
• Gross CP, Vogel EW, Dhond AJ, et al. Factors influencing physicians’ reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin Ther 2003;25:1750–64
   PubMed Web of Science ®Google Scholar
• Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897–902
   PubMed Web of Science ®Google Scholar
• Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004;164:880–4
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models and life tables. J R Statist Soc B 1972;34:187–220
   Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81
   Web of Science ®Google Scholar
• Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 2003;41:56–61
   PubMed Web of Science ®Google Scholar
• Devereaux PJ, Anderson DR, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001;323:1218–22
   PubMed Web of Science ®Google Scholar
• Howard PA, Ellerbeck EF, Engelman KK, et al. The nature and frequency of warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiol Drug Saf 2002;11:569–76
   PubMed Web of Science ®Google Scholar
• Brophy MT, Snyder KE, Gaehde S, et al. Anticoagulant use for atrial fibrillation in the elderly. J Am Geriatr Soc 2004;52:1151–6
   PubMed Web of Science ®Google Scholar
• Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449–57
   PubMed Web of Science ®Google Scholar
• Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Int Med 1999;131:492–501
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation. How well do randomized trials translate into clinical practice? JAMA 2003;290:2685–92
   Google Scholar
• Matchar DB, Samsa GP, Cohen SJ, et al. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med 2002;113:42–51
   PubMed Web of Science ®Google Scholar
• Fang, MC, Stafford RS, Ruskin JN, et al. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Int Med 2004;164:55–60
   PubMed Web of Science ®Google Scholar
• Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Int Med 2004;141:745–52
   PubMed Web of Science ®Google Scholar
• Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019–26
   PubMed Web of Science ®Google Scholar